SKYE Skye Bioscience Inc

Price (delayed)

$1.8

Market cap

$7.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.18

Enterprise value

$80,208

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 2

Skye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company’s ...

Highlights
Skye Bioscience's debt has shrunk by 51% YoY and by 43% QoQ
SKYE's EPS is down by 19% year-on-year but it is up by 12% since the previous quarter
Skye Bioscience's net income has decreased by 19% YoY but it has increased by 12% QoQ
The equity has plunged by 106% from the previous quarter and by 101% YoY
The company's quick ratio has shrunk by 85% YoY and by 47% QoQ

Key stats

What are the main financial stats of SKYE

SKYE stock price

How has the Skye Bioscience stock price performed over time
Intraday
5.26%
1 week
5.88%
1 month
-19.64%
1 year
-93.9%
YTD
-70%
QTD
-67.57%

Financial performance

How have Skye Bioscience's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.9M
Net income
-$50.49M
Gross margin
N/A
Net margin
N/A
Skye Bioscience's net income has decreased by 19% YoY but it has increased by 12% QoQ
SKYE's operating income is down by 14% YoY but it is up by 12% from the previous quarter

Price vs fundamentals

How does SKYE's price correlate with its fundamentals

Growth

What is Skye Bioscience's growth rate over time

Valuation

What is Skye Bioscience stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SKYE's EPS is down by 19% year-on-year but it is up by 12% since the previous quarter
The equity has plunged by 106% from the previous quarter and by 101% YoY

Efficiency

How efficient is Skye Bioscience business performance
The ROIC has plunged by 103% from the previous quarter and by 82% YoY
The company's return on equity has shrunk by 51% QoQ
The ROA has decreased by 24% from the previous quarter

Dividends

What is SKYE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SKYE.

Financial health

How did Skye Bioscience financials performed over time
The total assets is 4.3% smaller than the total liabilities
The company's quick ratio has shrunk by 85% YoY and by 47% QoQ
The current ratio has plunged by 84% YoY and by 47% from the previous quarter
Skye Bioscience's debt is 136% higher than its equity
The equity has plunged by 106% from the previous quarter and by 101% YoY
Skye Bioscience's debt has shrunk by 51% YoY and by 43% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.